Crohn's disease Trials in Palermo, Italy
Conditions / Crohn's disease / Palermo, Italy
Clinical trials for Crohn's disease investigate a range of treatment strategies and patient populations.
26 total trials for this combination
Showing top 10 of 26 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06430801 | A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) | RECRUITING | — |
| NCT03279081 | Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD) | COMPLETED | PHASE3 |
| NCT03345823 | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT01316939 | GSK1605786A in the Maintenance of Remission in Subjects With Crohn's Disease | TERMINATED | PHASE3 |
| NCT03105128 | A Study of the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Crohn's Disease | COMPLETED | PHASE3 |
| NCT03345836 | A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy | COMPLETED | PHASE3 |
| NCT03345849 | A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies | COMPLETED | PHASE3 |
| NCT03105102 | A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT05242471 | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease | ACTIVE_NOT_RECRUITING | PHASE2 |
| NCT06937099 | Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight | RECRUITING | — |